Developer docs
API playgroundTry for free, no card

Search company profiles

Eagle Genomics

Full company profile

uuid0003x1k

Namestring
Eagle Genomics
Legal namestring
Eagle Genomics
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Eagle Genomics is a UK-based TechBio company founded in 2008 that developed e[datascientist], an AI-augmented platform applying network science to microbiome data analysis. The platform addressed 'One Health' challenges spanning human, animal, and environmental health by enabling researchers and organizations to analyze complex microbial ecosystems, accelerate product development, and support evidence-based innovation across the discovery, development, and clinical validation lifecycle. The company targeted enterprise customers in four primary verticals: BioPharma (drug discovery and development), Food and Nutrition (product formulation and gut health), Beauty (skin microbiome research and cosmetic formulation), and AgBio (soil and plant microbiome analysis), with secondary applications in Healthcare and Consumer Products. Business model was enterprise B2B platform licensing/subscription with direct field sales targeting large organizations globally.

The company raised over £20 million in disclosed funding across multiple rounds dating back to 2013, with the largest being a USD 20 million scale-up round in October 2022 led by abrdn plc, followed by a £3 million round in September 2023 led by Granpool Innovative Investments. In September 2023, Dr Victoria Kimonides was appointed CEO and John Schoellerman as Chair. In January 2025, the company divested its core e[datascientist] platform to Cmbio via asset acquisition, and the company website is currently parked. Eagle Genomics remains technically operating but with its primary technology asset transferred to a third party.

Short descriptiontext

Eagle Genomics is a UK-based TechBio company that built e[datascientist], an AI-augmented network science platform for microbiome data analysis, serving enterprise customers in BioPharma, Food and Nutrition, Beauty, and AgBio. Its core platform was divested to Cmbio in January 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
microbiome data analytics, AI-augmented bioinformatics, network science platform, life sciences data management, techbio enterprise software
Industry2 codes
PRIMARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Bioinformatics Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Platform Licensing/Subscription
TypeSubscription Recurring
Description

The company operates a TechBio platform business model, generating revenue through licensing its e[datascientist] platform to enterprise customers in pharma, nutrition, beauty, and agriculture sectors

eaglegenomics.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1e[datascientist]
Description

AI-augmented microbiome science platform developed by Eagle Genomics for discovery, development, and clinical validation in the microbiome field

prnewswire.com
Core offering1 text field

Eagle Genomics developed and licensed the e[datascientist] platform, an AI-augmented microbiome science platform that applies network science to analyze complex microbial ecosystems. The platform enabled enterprise customers in BioPharma, Food and Nutrition, Beauty, and AgBio to perform microbiome research, AI-powered data analysis, and clinical validation across One Health challenges involving human, animal, and environmental health.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Eagle Genomics operated as a TechBio platform offering a single unified product: the e[datascientist] platform. This AI-augmented platform applies network science to microbiome science, enabling data-driven discovery and innovation across industries including Food and Nutrition, Beauty, AgBio, BioPharma, healthcare, agriculture, and consumer products. The platform supported the entire innovation lifecycle from discovery through development and clinical validation. In January 2025, the e[datascientist] platform was acquired by Cmbio.

Product and service1 record
1e[datascientist]
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-01-27
Description

Cmbio acquired Eagle Genomics' e[datascientist] platform in January 2025. This represents a significant licensing/asset acquisition where Cmbio obtained the platform technology to integrate into their Digital Biology offering combining multi-omics, AI, and systems biology capabilities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

DNAnexus provides a cloud-based bioinformatics and genomics data platform for life sciences R&D. Eagle Genomics' e[datascientist] platform played in the same category of AI-augmented scientific data management and analytics platforms serving pharma and life-science customers.

TypeDirect peer
Description

Benchling delivers a cloud-based R&D platform for biotech, with strong adoption across pharma and emerging biotech. It competes for the same enterprise life-sciences data management and workflow budget as Eagle Genomics' platform.

TypeDirect peer
Description

Genedata provides specialized bioinformatics and R&D data management software for pharma, agbio and industrial biotech. It overlaps directly with Eagle Genomics' enterprise software positioning for omics and microbiome analytics workflows.

TypeDirect peer
Description

Seven Bridges offers a bioinformatics platform for genomics and multi-omics data analysis, with customers in pharma and research. Comparable to Eagle Genomics' microbiome-focused AI-augmented analytics platform, particularly for large-scale life-sciences data.

TypeDirect peer
Description

Dotmatics offers a scientific R&D informatics platform spanning biology, chemistry, and formulation workflows. It is a direct enterprise-software peer competing for the same pharma/nutrition/AgBio R&D budgets that Eagle Genomics targeted.

TypeDirect peer
Description

CosmosID operates a microbial genomics and microbiome analytics platform using AI/ML for identification and characterization of microorganisms. Directly comparable to Eagle Genomics' e[datascientist] platform, which applied AI-augmented network science to microbiome data analysis.

TypeBroad incumbent
Description

QIAGEN's CLC bio portfolio offers industry-standard bioinformatics software for genomics, microbiome and multi-omics analysis. As a much larger incumbent with broader reach, it competes in the same analytics and interpretation layer that Eagle Genomics targeted.

TypeBroad incumbent
Description

Illumina provides sequencing platforms and downstream analytics (e.g., 16S/metagenomic workflows) used in microbiome research. While primarily a sequencing incumbent, its analytics stack overlaps with the consumer base of microbiome analytics platforms like Eagle Genomics.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eagle Genomics

Bioinformatics Softwareeaglegenomics.com

Eagle Genomics is a UK-based TechBio company that built e[datascientist], an AI-augmented network science platform for microbiome data analysis, serving enterprise customers in BioPharma, Food and Nutrition, Beauty, and AgBio. Its core platform was divested to Cmbio in January 2025.

What Eagle Genomics does

Eagle Genomics is a UK-based TechBio company founded in 2008 that developed e[datascientist], an AI-augmented platform applying network science to microbiome data analysis. The platform addressed 'One Health' challenges spanning human, animal, and environmental health by enabling researchers and organizations to analyze complex microbial ecosystems, accelerate product development, and support evidence-based innovation across the discovery, development, and clinical validation lifecycle. The company targeted enterprise customers in four primary verticals: BioPharma (drug discovery and development), Food and Nutrition (product formulation and gut health), Beauty (skin microbiome research and cosmetic formulation), and AgBio (soil and plant microbiome analysis), with secondary applications in Healthcare and Consumer Products. Business model was enterprise B2B platform licensing/subscription with direct field sales targeting large organizations globally.

The company raised over £20 million in disclosed funding across multiple rounds dating back to 2013, with the largest being a USD 20 million scale-up round in October 2022 led by abrdn plc, followed by a £3 million round in September 2023 led by Granpool Innovative Investments. In September 2023, Dr Victoria Kimonides was appointed CEO and John Schoellerman as Chair. In January 2025, the company divested its core e[datascientist] platform to Cmbio via asset acquisition, and the company website is currently parked. Eagle Genomics remains technically operating but with its primary technology asset transferred to a third party.

Eagle Genomics firmographics

Firmographics
Name
Eagle Genomics
Legal name
Eagle Genomics
Website
https://eaglegenomics.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Eagle Genomics is a UK-based TechBio company that built e[datascientist], an AI-augmented network science platform for microbiome data analysis, serving enterprise customers in BioPharma, Food and Nutrition, Beauty, and AgBio. Its core platform was divested to Cmbio in January 2025.
Ownership category
akta.pro rank

Eagle Genomics industry classification

Industry
Product category
Bioinformatics Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Microbiome data analytics
  • AI-augmented bioinformatics
  • Network science platform
  • Life sciences data management
  • Techbio enterprise software

Where Eagle Genomics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Markets served

Eagle Genomics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Platform Licensing/Subscription: The company operates a TechBio platform business model, generating revenue through licensing its e[datascientist] platform to enterprise customers in pharma, nutrition, beauty, and agriculture sectors

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Eagle Genomics product offering

Product offering

Core offering

Eagle Genomics developed and licensed the e[datascientist] platform, an AI-augmented microbiome science platform that applies network science to analyze complex microbial ecosystems. The platform enabled enterprise customers in BioPharma, Food and Nutrition, Beauty, and AgBio to perform microbiome research, AI-powered data analysis, and clinical validation across One Health challenges involving human, animal, and environmental health.

Product overview

Eagle Genomics operated as a TechBio platform offering a single unified product: the e[datascientist] platform. This AI-augmented platform applies network science to microbiome science, enabling data-driven discovery and innovation across industries including Food and Nutrition, Beauty, AgBio, BioPharma, healthcare, agriculture, and consumer products. The platform supported the entire innovation lifecycle from discovery through development and clinical validation. In January 2025, the e[datascientist] platform was acquired by Cmbio.

Differentiator

Problem solved

Functional benefit

Brands

  • e[datascientist]: AI-augmented microbiome science platform developed by Eagle Genomics for discovery, development, and clinical validation in the microbiome field

Products and services

  • e[datascientist]

Companies that use Eagle Genomics

Customer profile

Segments6 records

Ideal customer profiles4 records

Eagle Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Eagle Genomics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CmbiomajorOEM/ Whitelabel/ Licensing Partner · 27 January 2025Cmbio acquired Eagle Genomics' e[datascientist] platform in January 2025. This represents a significant licensing/asset acquisition where Cmbio obtained the platform technology to integrate into their Digital Biology offering combining multi-omics, AI, and systems biology capabilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Eagle Genomics competitors and assessment

Company assessment

Direct peers

  • DNAnexus: DNAnexus provides a cloud-based bioinformatics and genomics data platform for life sciences R&D. Eagle Genomics' e[datascientist] platform played in the same category of AI-augmented scientific data management and analytics platforms serving pharma and life-science customers.
  • Benchling: Benchling delivers a cloud-based R&D platform for biotech, with strong adoption across pharma and emerging biotech. It competes for the same enterprise life-sciences data management and workflow budget as Eagle Genomics' platform.
  • Genedata: Genedata provides specialized bioinformatics and R&D data management software for pharma, agbio and industrial biotech. It overlaps directly with Eagle Genomics' enterprise software positioning for omics and microbiome analytics workflows.
  • Seven Bridges Genomics: Seven Bridges offers a bioinformatics platform for genomics and multi-omics data analysis, with customers in pharma and research. Comparable to Eagle Genomics' microbiome-focused AI-augmented analytics platform, particularly for large-scale life-sciences data.
  • Dotmatics: Dotmatics offers a scientific R&D informatics platform spanning biology, chemistry, and formulation workflows. It is a direct enterprise-software peer competing for the same pharma/nutrition/AgBio R&D budgets that Eagle Genomics targeted.
  • CosmosID: CosmosID operates a microbial genomics and microbiome analytics platform using AI/ML for identification and characterization of microorganisms. Directly comparable to Eagle Genomics' e[datascientist] platform, which applied AI-augmented network science to microbiome data analysis.

Broad incumbents

  • QIAGEN (CLC bio): QIAGEN's CLC bio portfolio offers industry-standard bioinformatics software for genomics, microbiome and multi-omics analysis. As a much larger incumbent with broader reach, it competes in the same analytics and interpretation layer that Eagle Genomics targeted.
  • Illumina (microbiome analytics): Illumina provides sequencing platforms and downstream analytics (e.g., 16S/metagenomic workflows) used in microbiome research. While primarily a sequencing incumbent, its analytics stack overlaps with the consumer base of microbiome analytics platforms like Eagle Genomics.

Market position

Strengths3 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Eagle Genomics social profiles

Digital presence

Eagle Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eagle Genomics leadership team

Management profile

Number of profiles

Profiles6 records

Eagle Genomics funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eagle Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eagle Genomics

What does Eagle Genomics do?

Eagle Genomics developed and licensed the e[datascientist] platform, an AI-augmented microbiome science platform that applies network science to analyze complex microbial ecosystems. The platform enabled enterprise customers in BioPharma, Food and Nutrition, Beauty, and AgBio to perform microbiome research, AI-powered data analysis, and clinical validation across One Health challenges involving human, animal, and environmental health.

Is Eagle Genomics a public or private company?

Eagle Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Eagle Genomics founded?

Eagle Genomics was founded in 2008. It employs 11 to 50 people.

Where is Eagle Genomics based?

Eagle Genomics is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Eagle Genomics make money?

One revenue line is on record: platform Licensing/Subscription.

Who are Eagle Genomics's main competitors?

Direct peers on record are DNAnexus, Benchling, Genedata, Seven Bridges Genomics, Dotmatics and CosmosID. Broad incumbents are QIAGEN (CLC bio) and Illumina (microbiome analytics).

Does Eagle Genomics have an API?

No public API is recorded for Eagle Genomics.

What industry is Eagle Genomics in?

Eagle Genomics's product category is Bioinformatics Software. Its primary akta.pro industry code is HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms, with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EitfoodTop 5 food tech innovations in targeted nutritionThe article highlights five food technology innovations in Europe focused on targeted nutrition, including LOEWI's blood-based supplements, Royal DSM's Hologram Sciences platform, BeYou's AI health coaching, the PROTEIN data system, and Eagle Genomics' microbiome solutions. These developments aim to address global health challenges like obesity and non-communicable diseases by providing personalized dietary guidance and products based on individual diagnostics. The innovations represent a growing sector where science and technology converge to offer tailored wellness interventions.EaglegenomicsFundraising extension to >£20m for Eagle Genomics and appointment of new leadershipEagle Genomics announced a £3 million fundraising extension, bringing its total capital raised to over £20 million, alongside the appointment of Dr Victoria Kimonides as CEO and John Schoellerman as Board Chair. The company intends to use the funds to deploy its software platform for corporate microbiome research monetization.PharmiWeb.comFundraising extension to >£20m for Eagle Genomics and appointment of new leadershipEagle Genomics announced it has raised an additional £3 million in financing, bringing its total capital raised over the last 12 months to over £20 million, with continued participation from investors including abrdn plc and Granpool Innovative Investments. The company simultaneously appointed Dr Victoria Kimonides as its new CEO and John Schoellerman as Board Chair to lead its microbiome software platform strategy.BusinessLineICRISAT, Eagle Genomics sign pactICRISAT and Eagle Genomics signed an MoU to collaborate on life science and data science for food security. The agreement will have ICRISAT share field datasets with Eagle Genomics. The partnership aims to enhance nutrient density in crops for drought-prone dryland areas.PR NewswireICRISAT and Eagle Genomics partnership to accelerate microbiome-based solutions to drive global climate resilience, sustainable food systems and improved nutritionICRISAT and Eagle Genomics signed a Memorandum of Understanding at the International Conference on Innovations to Transform Drylands in Hyderabad, India, establishing a public-private partnership to accelerate microbiome-based solutions for climate resilience and sustainable food systems. The collaboration will leverage Eagle Genomics' AI-augmented e[datascientist]™ platform with ICRISAT's half-century of agricultural research data spanning Asia and Africa to develop nature-based solutions addressing food security and malnutrition. The partnership aims to benefit over two billion people living in dryland regions by improving plant nutrient density, enhancing soil health, and advancing regenerative agriculture through data-driven microbiome science.FinSMEsEagle Genomics Raises Funding from Omron VenturesEagle Genomics, a Cambridge-based TechBio platform, raised an undisclosed amount from Omron Ventures. The company will use the funds for platform development and global expansion. The funding round is ongoing, with additional investment opportunities open.PR NewswireEagle Genomics' Scale-Up Funding from OMRON Ventures to Drive Sustainability Innovation in Microbiome R&DOMRON Ventures, a Japan-based corporate venture capital firm, announced additional scale-up funding for Eagle Genomics, a UK-headquartered TechBio company, to support development of its e[datascientist]™ AI-augmented knowledge discovery platform and continued global expansion. The funding round, which follows a USD $20 million first close in October 2022 led by abrdn plc, also includes continued participation from existing investors Environmental Technologies Fund and a consortium led by Granpool Innovative Investments. Eagle Genomics applies network science and AI to microbiome research across the Food and Nutrition, AgBio, Beauty and Personal Care, and Biopharma industries, supporting enterprise customers in addressing 'One Health' challenges through sustainable innovation.EaglegenomicsEagle Genomics’ Scale-Up Funding from OMRON Ventures to Drive Sustainability Innovation in Microbiome R&DEagle Genomics has secured additional scale-up funding from Japan-based OMRON Ventures to enhance its AI-augmented knowledge discovery platform, e[datascientist]™, and support its global expansion. The funding will enable Eagle Genomics to drive innovations in microbiome research across various industries, including Food and Nutrition, AgBio, and Biopharma. This investment aligns with OMRON's goals of leveraging data to create social and economic value, emphasizing the interconnected health of humans, animals, and the environment.PR NewswireEagle Genomics' Scale-Up Funding from OMRON Ventures to Drive Sustainability Innovation in Microbiome R&DEagle Genomics announced additional scale-up funding from OMRON Ventures to support the development of its AI-augmented e[datascientist] platform and global expansion. This investment follows a previous USD $20 million close led by abrdn, with participation from Environmental Technologies Fund and Granpool Innovative Investments. The funds aim to advance microbiome research applications across food, beauty, agriculture, and biopharma sectors.FinSMEsEagle Genomics Raises USD20M First Close of FundingEagle Genomics secured a USD 20 million first close for its scale-up funding round, led by abrdn plc with participation from existing investors. The capital will support the development of its e[datascientist]™ AI platform and facilitate expansion into global markets. Additional investment opportunities remain open for up to USD 10 million.